Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
🎥 This #WorldLeukemiaDay watch @zucenka (@VU_LT) discuss data from a study investigating venetoclax combinations in FLT3- and IDH1-mutated acute myeloid #Leukemia:
As it's #WorldLeukemiaDay, why not listen to our recent podcast episode on the sequencing of BTKi therapy in CLL, which focuses on treatment considerations and emerging strategies.🩸
Click here to check it out:
🎧 https://ow.ly/8J5y50ZAsJV
🚨 The FDA approves ropeginterferon alfa-2b for the treatment of essential thrombocythemia!
This approval introduces the first new FDA-approved treatment for ET in nearly 3 decades, offering a long-acting interferon-based approach supported by durable response and hematologic
🧬 AAV gene therapy in hemophilia: what comes next?
Hear @RKaczmarekDr discuss the challenges of current AAV-based approaches, including durability, liver toxicity, and potential malignancy risks, alongside emerging non-AAV strategies.
🎥 This #WorldLeukemiaDay watch @zucenka (@VU_LT) discuss data from a study investigating venetoclax combinations in FLT3- and IDH1-mutated acute myeloid #Leukemia:
As it's #WorldLeukemiaDay, why not listen to our recent podcast episode on the sequencing of BTKi therapy in CLL, which focuses on treatment considerations and emerging strategies.🩸
Click here to check it out:
🎧 https://ow.ly/8J5y50ZAsJV
🚨 The FDA approves ropeginterferon alfa-2b for the treatment of essential thrombocythemia!
This approval introduces the first new FDA-approved treatment for ET in nearly 3 decades, offering a long-acting interferon-based approach supported by durable response and hematologic
🧬 AAV gene therapy in hemophilia: what comes next?
Hear @RKaczmarekDr discuss the challenges of current AAV-based approaches, including durability, liver toxicity, and potential malignancy risks, alongside emerging non-AAV strategies.
In this roundtable discussion, leading CLL experts Paolo Ghia, Susan O’Brien, Lydia Scarfo and Othman Al-Sawaf review the latest and most exciting updates in the field of CLL from the 2021 EHA and ICML meetings.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.